Results from the Phase II COLLECTiVE202 trial (NCT05370885) demonstrated a statistically significant difference between VE202 ...

In this Q&A, Rohit Nambisan, CEO of Lokavant, and Jonathan Crowther, head of predictive analytics, Pfizer, explore how AI is ...

Management reiterated the expectation that Elfabrio royalties will exceed $100 million by 2030, based on a projected 15% to 20% market share of the Fabry disease market.

HHS' decision "could stagnate research that has the potential to save millions of lives," writes Simon Williams.

Schrödinger has halted development of its cancer-fighting candidate SGR-2921 after two patients treated with the CDC7 inhibitor died in a Phase I trial.

Q2 2025 Earnings Call Transcript August 14, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-3 ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.

August 14, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL ® siRNA gene silencing technology to ...

Net loss (GAAP) narrowed to $6.1 million in Q2 2025, a 22.8% improvement from the prior-year period, driven by reduced research and development spending. No product revenue reported; The company’s ...

GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and ...

Cancer is not solely a disease of uncontrolled cell proliferation, but also one of immune system failure. The concept of cancer immunoediting—comprising the ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...